Detalhe da pesquisa
1.
The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome.
Cell;
182(2): 329-344.e19, 2020 07 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32589946
2.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature;
595(7867): 432-437, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34135506
3.
TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature;
554(7693): 544-548, 2018 02 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29443960
4.
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
Prostate;
82(9): 993-1002, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35435276
5.
Taking cohesin and condensin in context.
PLoS Genet;
14(1): e1007118, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29370184
6.
Mef2c-F10N enhancer driven ß-galactosidase (LacZ) and Cre recombinase mice facilitate analyses of gene function and lineage fate in neural crest cells.
Dev Biol;
402(1): 3-16, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25794678
7.
Lack of TGFß signaling competency predicts immune poor cancer conversion to immune rich and response to checkpoint blockade.
bioRxiv;
2024 May 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38496519
8.
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Cell Rep Med;
5(2): 101393, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38280376
9.
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Clin Cancer Res;
29(21): 4373-4384, 2023 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37651261
10.
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Cell Rep Med;
4(1): 100878, 2023 01 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36599350
11.
Cell-based receptor discovery identifies host factors specifically targeted by the SARS CoV-2 spike.
Commun Biol;
5(1): 788, 2022 08 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35931765
12.
Single-cell analysis reveals clonally expanded tumor-associated CD57+ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade.
J Immunother Cancer;
10(8)2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35981786
13.
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.
Nat Med;
28(1): 144-153, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35013615
14.
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res;
27(17): 4746-4756, 2021 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34108181
15.
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Clin Cancer Res;
27(12): 3360-3369, 2021 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33568344
16.
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer.
Cancer Immunol Res;
8(7): 844-850, 2020 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32321776
17.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med;
26(5): 693-698, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32405063
18.
Measurement of RNA-induced PKR Activation in vitro.
Bio Protoc;
7(6): e2178, 2017 Mar 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34458488
19.
Condensin II is anchored by TFIIIC and H3K4me3 in the mammalian genome and supports the expression of active dense gene clusters.
Sci Adv;
3(6): e1700191, 2017 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28691095
20.
NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR.
Cell Rep;
14(1): 93-102, 2016 Jan 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26725122